Immune-tolerated therapeutic proteins
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
34
NCT04602390
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 6, 2020
Completion: Apr 23, 2024
Loading map...